[go: up one dir, main page]

MA32892B1 - Anticorps anti-cmet - Google Patents

Anticorps anti-cmet

Info

Publication number
MA32892B1
MA32892B1 MA33933A MA33933A MA32892B1 MA 32892 B1 MA32892 B1 MA 32892B1 MA 33933 A MA33933 A MA 33933A MA 33933 A MA33933 A MA 33933A MA 32892 B1 MA32892 B1 MA 32892B1
Authority
MA
Morocco
Prior art keywords
antibody
receptor
cmet
antibodies
met
Prior art date
Application number
MA33933A
Other languages
Arabic (ar)
English (en)
Inventor
Liliane Goetsch
Thierry Wurch
Cédric Bes
Original Assignee
Pf Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41693124&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA32892(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/IB2008/055663 external-priority patent/WO2010064089A1/fr
Application filed by Pf Medicament filed Critical Pf Medicament
Publication of MA32892B1 publication Critical patent/MA32892B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Connection Of Motors, Electrical Generators, Mechanical Devices, And The Like (AREA)

Abstract

L'invention concerne un anticorps capable de se lier spécifiquement au récepteur c-MET humain et/ou d'inhiber spécifiquement l'activité de tyrosine kinase dudit récepteur, avec une meilleure activité antagoniste, ledit anticorps comprenant une zone charnière modifiée. L'invention concerne également une composition comprenant un tel anticorps antagoniste de c-MET et son utilisation comme médicament pour le traitement du cancer.
MA33933A 2008-12-02 2011-06-10 Anticorps anti-cmet MA32892B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/IB2008/055663 WO2010064089A1 (fr) 2008-12-02 2008-12-02 Nouvel anticorps anti-cmet
US18450209P 2009-06-05 2009-06-05
PCT/EP2009/066201 WO2010069765A1 (fr) 2008-12-02 2009-12-02 Anticorps anti-cmet

Publications (1)

Publication Number Publication Date
MA32892B1 true MA32892B1 (fr) 2011-12-01

Family

ID=41693124

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33933A MA32892B1 (fr) 2008-12-02 2011-06-10 Anticorps anti-cmet

Country Status (38)

Country Link
US (4) US8741290B2 (fr)
EP (4) EP3135691B1 (fr)
JP (3) JP5863458B2 (fr)
KR (1) KR101838299B1 (fr)
CN (2) CN102227446B (fr)
AR (1) AR074439A1 (fr)
AU (3) AU2009328318C1 (fr)
BR (2) BRPI0923231B8 (fr)
CA (1) CA2743433C (fr)
CL (2) CL2011001296A1 (fr)
CO (1) CO6382139A2 (fr)
CR (1) CR20110324A (fr)
CY (2) CY1119172T1 (fr)
DK (2) DK3135691T3 (fr)
EC (1) ECSP11011127A (fr)
ES (3) ES2629855T3 (fr)
GE (2) GEP20146207B (fr)
HR (2) HRP20171011T8 (fr)
HU (3) HUE051288T2 (fr)
IL (2) IL213273A0 (fr)
LT (2) LT3135691T (fr)
MA (1) MA32892B1 (fr)
MX (2) MX2011005677A (fr)
MY (2) MY185200A (fr)
NZ (1) NZ593853A (fr)
PE (1) PE20120343A1 (fr)
PH (1) PH12015501515A1 (fr)
PL (3) PL3431502T3 (fr)
PT (3) PT2370468T (fr)
RS (2) RS58018B1 (fr)
RU (2) RU2560257C2 (fr)
SA (2) SA109300720B1 (fr)
SG (2) SG187518A1 (fr)
SI (3) SI3135691T1 (fr)
TN (1) TN2011000216A1 (fr)
TW (2) TWI523866B (fr)
WO (1) WO2010069765A1 (fr)
ZA (1) ZA201105164B (fr)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2014681A1 (fr) 2007-07-12 2009-01-14 Pierre Fabre Medicament Nouveaux anticorps à inhibition de dimérisation c-met, et utilisations correspondantes
US8545839B2 (en) * 2008-12-02 2013-10-01 Pierre Fabre Medicament Anti-c-Met antibody
EP2287197A1 (fr) * 2009-08-21 2011-02-23 Pierre Fabre Medicament Anticorps anti-cMET et son utilisation pour la détection et le diagnostic du cancer
US9068011B2 (en) 2010-03-10 2015-06-30 Genmab A+S Monoclonal antibodies against c-Met
AU2011296085A1 (en) 2010-09-03 2013-03-28 Academia Sinica Anti-c-Met antibody and methods of use thereof
WO2012059562A1 (fr) 2010-11-03 2012-05-10 Argen-X-Bv Combinaisons d'anticorps c-met
EP2710042A2 (fr) 2011-05-16 2014-03-26 Fabion Pharmaceuticals, Inc. Protéines de fusion contenant un fab multi-spécifique et procédé d'utilisation
KR101865223B1 (ko) 2011-10-05 2018-06-08 삼성전자주식회사 항 ｃ-Ｍｅｔ 인간화 항체 및 그의 용도
KR20130036993A (ko) * 2011-10-05 2013-04-15 삼성전자주식회사 ｃ-Ｍｅｔ의 ＳＥＭＡ 도메인 내의 에피토프에 특이적으로 결합하는 항체
WO2013064700A2 (fr) 2011-11-03 2013-05-10 Argen-X B.V. Polypeptides chimériques et leurs procédés d'utilisation
KR101463098B1 (ko) 2011-11-28 2014-11-27 한국생명공학연구원 ｃ-Ｍｅｔ에 대한 인간항체에 약물이 접합된 약물 복합체 및 이의 용도
KR101910601B1 (ko) 2011-12-22 2018-10-23 삼성전자주식회사 면역원성이 제거된 항 ｃ-Ｍｅｔ 인간화 항체 및 그의 용도
CA2877573A1 (fr) * 2012-06-21 2013-12-27 Sorrento Therapeutics, Inc. Proteines de liaison a un antigene qui se lient a c-met
US9931400B2 (en) 2012-09-12 2018-04-03 Samsung Electronics Co., Ltd. Method of combination therapy for prevention or treatment of c-Met or angiogenesis factor induced diseases
ES2530968T3 (es) 2012-10-12 2015-03-09 Spirogen Sarl Pirrolobenzodiazepinas y conjugados de las mismas
WO2014140174A1 (fr) 2013-03-13 2014-09-18 Spirogen Sàrl Pyrrolobenzodiazépines et leurs conjugués
KR102049990B1 (ko) * 2013-03-28 2019-12-03 삼성전자주식회사 c-Met 항체 및 VEGF 결합 단편이 연결된 융합 단백질
US9994644B2 (en) 2013-04-30 2018-06-12 Agency For Science, Technology And Research mAB 2 anti-Met antibody
US9567641B2 (en) * 2013-07-03 2017-02-14 Samsung Electronics Co., Ltd. Combination therapy for the treatment of cancer using an anti-C-met antibody
US9717715B2 (en) 2013-11-15 2017-08-01 Samsung Electronics Co., Ltd. Method of combination therapy using an anti-C-Met antibody
RU2656153C1 (ru) * 2013-12-20 2018-05-31 Девелопмент Сентер Фор Байотекнолоджи Антитела, специфичные к альфа-энолазе, и способы применения в противоопухолевой терапии
JP6531166B2 (ja) 2014-09-10 2019-06-12 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ ピロロベンゾジアゼピン及びそのコンジュゲート
EP3270918A4 (fr) * 2015-03-16 2018-10-24 Celldex Therapeutics, Inc. Anticorps anti-met et procédés d'utilisation de ceux-ci
ES2896709T3 (es) * 2016-02-05 2022-02-25 Helixmith Co Ltd Anticuerpos anti-c-Met y usos de los mismos
CA3017776A1 (fr) 2016-03-15 2017-09-21 Generon (Shanghai) Corporation Ltd. Proteines de fusion a fab multispecifiques et leur utilisation
NZ748314A (en) * 2016-05-17 2023-07-28 Abbvie Inc Anti-cmet antibody drug conjugates and methods for their use
US10457726B2 (en) 2016-06-30 2019-10-29 University Of Connecticut Antibody and antigen-binding fragment compositions targeting cell surface antigens in tumors and methods of use thereof
WO2018069289A1 (fr) 2016-10-11 2018-04-19 Medimmune Limited Conjugués anticorps-médicament associés à des agents thérapeutiques à médiation immunitaire
RU2741228C2 (ru) * 2016-11-14 2021-01-22 Общество С Ограниченной Ответственностью "Панацела Лабс" Противоопухолевые эффекты вирусного вектора, кодирующего толл-подобный рецептор и агонист толл-подобного рецептора
TWI782930B (zh) 2016-11-16 2022-11-11 美商再生元醫藥公司 抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法
WO2018129029A1 (fr) * 2017-01-04 2018-07-12 Immunogen, Inc. Anticorps anti-met, immunoconjugués et utilisations de ceux-ci
CN109771642B (zh) 2017-11-13 2022-09-20 同济大学苏州研究院 c-MET激动型抗体及其用途
GB201803892D0 (en) * 2018-03-12 2018-04-25 Ultrahuman Six Ltd C-met binding agents
CN113286616A (zh) 2018-05-23 2021-08-20 Adc治疗有限公司 分子佐剂
AU2019318087B2 (en) * 2018-08-08 2025-09-18 Dragonfly Therapeutics, Inc. Proteins binding NKG2D, CD 16 and a tumor-associated antigen
EP3847196A4 (fr) 2018-09-07 2023-01-04 ITabMed (HK) Limited Protéines de liaison à un antigène bispécifiques et leurs utilisations
CN109541221B (zh) * 2018-10-24 2022-03-22 益善生物技术股份有限公司 一种c-Met特异性抗体、组合物及试剂盒
KR102353568B1 (ko) * 2018-11-14 2022-01-20 주식회사 헬릭스미스 안정성이 향상된 항 c-Met 항체 또는 그의 항원 결합 단편
WO2020198731A2 (fr) * 2019-03-28 2020-10-01 Danisco Us Inc Anticorps modifiés
MX2022002886A (es) 2019-09-16 2022-04-06 Regeneron Pharma Proteinas de union met radiomarcadas para la obtencion de imagenes por inmuno-pet.
KR20230018454A (ko) 2020-09-01 2023-02-07 레메젠 코, 리미티드 항-c-Met 항체-약물 접합체 및 이의 용도
WO2022079211A1 (fr) 2020-10-16 2022-04-21 Adc Therapeutics Sa Glycoconjugués
GB202102396D0 (en) 2021-02-19 2021-04-07 Adc Therapeutics Sa Molecular adjuvant
WO2022216796A1 (fr) 2021-04-06 2022-10-13 Abbvie Biotherapeutics Inc. Méthodes de traitement du cancer du poumon non à l'aide de telisotuzumab vedotin
US20240376214A1 (en) * 2021-04-08 2024-11-14 Byondis B.V. Anti-c-met antibodies and antibody-drug conjugates
AR125473A1 (es) 2021-04-29 2023-07-19 Abbvie Inc Conjugados de anticuerpo anti-c-met y fármaco
EP4426727A2 (fr) 2021-11-03 2024-09-11 Hangzhou Dac Biotech Co., Ltd. Conjugaison spécifique d'un anticorps
US20230285394A1 (en) 2022-03-11 2023-09-14 Abbvie Biotherapeutics Inc. Methods of treatment of non-small-cell lung carcinoma using telisotuzummab vedotin and osimertinib
WO2024243450A1 (fr) 2023-05-23 2024-11-28 Abbvie Inc. Méthodes de traitement utilisant des conjugués anticorps-médicament anti-c-met
WO2025149667A1 (fr) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Conjugués anticorps-médicament et leurs utilisations

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4424200A (en) 1979-05-14 1984-01-03 Nuc Med Inc. Method for radiolabeling proteins with technetium-99m
US4479930A (en) 1982-07-26 1984-10-30 Trustees Of The University Of Massachusetts Amines coupled wth dicyclic dianhydrides capable of being radiolabeled product
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4831175A (en) 1986-09-05 1989-05-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
GB8924581D0 (en) 1989-11-01 1989-12-20 Pa Consulting Services Bleaching of hair
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
WO1994004679A1 (fr) * 1991-06-14 1994-03-03 Genentech, Inc. Procede pour fabriquer des anticorps humanises
JPH05244982A (ja) 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
US5639641A (en) * 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US5686292A (en) * 1995-06-02 1997-11-11 Genentech, Inc. Hepatocyte growth factor receptor antagonist antibodies and uses thereof
WO2002055106A2 (fr) * 2001-01-09 2002-07-18 Merck Patent Gmbh Polytherapie faisant appel a des inhibiteurs de recepteurs tyrosine kinase et a des inhibiteurs d'angiogenese
WO2004072117A2 (fr) * 2003-02-13 2004-08-26 Pharmacia Corporation Anticorps contre c-met dans le traitement de cancers
HN2004000285A (es) 2003-08-04 2006-04-27 Pfizer Prod Inc ANTICUERPOS DIRIGIDOS A c-MET
US20050233960A1 (en) 2003-12-11 2005-10-20 Genentech, Inc. Methods and compositions for inhibiting c-met dimerization and activation
PT1773885E (pt) * 2004-08-05 2010-07-21 Genentech Inc Antagonistas anti-cmet humanizados
US8008443B2 (en) * 2005-04-26 2011-08-30 Medimmune, Llc Modulation of antibody effector function by hinge domain engineering
KR20130023356A (ko) * 2005-07-18 2013-03-07 메다렉스, 인코포레이티드 인간 항-ｂ7ｒｐ1 중화 항체
EP1913027B1 (fr) * 2005-07-28 2015-03-04 Novartis AG Anticorps monoclonal specifique de m-csf et ses utilisations
JP5536445B2 (ja) * 2006-03-30 2014-07-02 ノバルティス アーゲー ｃ−Ｍｅｔの抗体の組成物およびその使用方法
EP2014681A1 (fr) * 2007-07-12 2009-01-14 Pierre Fabre Medicament Nouveaux anticorps à inhibition de dimérisation c-met, et utilisations correspondantes
US8545839B2 (en) 2008-12-02 2013-10-01 Pierre Fabre Medicament Anti-c-Met antibody

Also Published As

Publication number Publication date
RU2011124751A (ru) 2013-01-10
BR122019023930B1 (pt) 2021-05-04
TWI459964B (zh) 2014-11-11
CN102227446A (zh) 2011-10-26
RU2560257C2 (ru) 2015-08-20
US20130109844A1 (en) 2013-05-02
DK2370468T3 (en) 2017-06-19
US8765128B2 (en) 2014-07-01
AU2016200725C1 (en) 2017-10-19
AU2017203929A1 (en) 2017-07-06
CN102227446B (zh) 2015-10-21
RS56204B1 (sr) 2017-11-30
JP5863458B2 (ja) 2016-02-16
PT3135691T (pt) 2018-11-27
MY185200A (en) 2021-04-30
KR20110097839A (ko) 2011-08-31
CA2743433A1 (fr) 2010-06-24
AR074439A1 (es) 2011-01-19
JP6074018B2 (ja) 2017-02-01
IL231525A0 (en) 2014-04-30
CY1121025T1 (el) 2019-12-11
PH12015501515A1 (en) 2015-12-14
HK1162536A1 (zh) 2012-08-31
EP3431502A1 (fr) 2019-01-23
PL3431502T3 (pl) 2020-12-28
RS58018B1 (sr) 2019-02-28
KR101838299B1 (ko) 2018-03-14
AU2009328318C1 (en) 2017-11-02
PT3431502T (pt) 2020-10-29
MX2011005677A (es) 2011-06-30
AU2009328318B2 (en) 2015-11-05
SA109300720B1 (ar) 2013-05-25
EP3135691A1 (fr) 2017-03-01
US8729249B2 (en) 2014-05-20
SI2370468T1 (sl) 2017-08-31
CN103351438B (zh) 2016-04-20
US20110239316A1 (en) 2011-09-29
HK1190414A1 (zh) 2014-07-04
CL2014000181A1 (es) 2014-07-25
WO2010069765A1 (fr) 2010-06-24
ES2697098T3 (es) 2019-01-22
MY192567A (en) 2022-08-29
HUE051288T2 (hu) 2021-03-01
BRPI0923231A2 (pt) 2016-01-26
EP3757132A1 (fr) 2020-12-30
GEP20146207B (en) 2014-12-10
TW201023892A (en) 2010-07-01
CO6382139A2 (es) 2012-02-15
SA112331005B1 (ar) 2015-09-13
TWI523866B (zh) 2016-03-01
HRP20171011T8 (hr) 2019-01-25
IL213273A0 (en) 2011-07-31
ES2629855T3 (es) 2017-08-16
NZ593853A (en) 2013-03-28
US20130109841A1 (en) 2013-05-02
HRP20181868T1 (hr) 2019-01-11
JP2017099392A (ja) 2017-06-08
TW201446805A (zh) 2014-12-16
JP2012510280A (ja) 2012-05-10
PE20120343A1 (es) 2012-04-16
US8741290B2 (en) 2014-06-03
ZA201105164B (en) 2012-03-28
US20130109840A1 (en) 2013-05-02
SI3431502T1 (sl) 2021-01-29
SG171851A1 (en) 2011-07-28
HUE035047T2 (en) 2018-05-02
SG187518A1 (en) 2013-02-28
IL231525B (en) 2019-07-31
EP2370468A1 (fr) 2011-10-05
EP3135691B1 (fr) 2018-08-15
AU2016200725A1 (en) 2016-02-25
PT2370468T (pt) 2017-07-13
AU2009328318A1 (en) 2011-07-28
ES2827277T3 (es) 2021-05-20
BRPI0923231B1 (pt) 2020-04-28
TN2011000216A1 (en) 2012-12-17
CL2011001296A1 (es) 2011-08-26
BRPI0923231B8 (pt) 2021-05-25
PL2370468T3 (pl) 2017-09-29
US8747850B2 (en) 2014-06-10
EP3431502B1 (fr) 2020-07-22
GEP20135930B (en) 2013-10-10
ECSP11011127A (es) 2011-07-29
EP2370468B1 (fr) 2017-04-05
SI3135691T1 (sl) 2018-12-31
JP2016117721A (ja) 2016-06-30
MX341014B (es) 2016-08-03
LT3135691T (lt) 2018-11-12
CY1119172T1 (el) 2018-02-14
CR20110324A (es) 2011-07-28
PL3135691T3 (pl) 2019-02-28
CN103351438A (zh) 2013-10-16
AU2016200725B2 (en) 2017-05-25
DK3135691T3 (en) 2018-11-19
JP6309657B2 (ja) 2018-04-11
AU2017203929B2 (en) 2019-03-28
RU2015127471A (ru) 2018-12-21
LT2370468T (lt) 2017-07-10
HUE040553T2 (hu) 2019-03-28
CA2743433C (fr) 2019-06-11
HRP20171011T1 (hr) 2017-09-22

Similar Documents

Publication Publication Date Title
MA32892B1 (fr) Anticorps anti-cmet
MA31899B1 (fr) Anticorps monoclonaux qui se lient au hgm-csf et compositions medicales les comprenant
ATE442850T1 (de) Kappa-opioid-rezeptor-liganden
MA34289B1 (fr) Nouvel anticorps anti-cmet
DE60225673D1 (de) Kappa-opioid-rezeptor-liganden
MX2007002675A (es) Antagonistas anti-beta7 humanizados y usos para los mismos.
GEP20074252B (en) Antibodies to vla-1
EA200870410A1 (ru) Антагонисты киназы
MA44334A (fr) Conjugués d'anticorps comprenant un agoniste du récepteur de type toll
SG196835A1 (en) Human anti-b7rp1 neutralizing antibodies
MX2010005031A (es) Anticuerpos de axl.
MA32099B1 (fr) Composition comprenant un anticorps se liant au domaine ii de her2 et variantes acides de celle-ci
IL214325A0 (en) Humanized anti-cmet antagonists
MA34555B1 (fr) Nouvelles protéines de liaison à un antigène
MA37761A1 (fr) Protéines de liaison à un antigène antagoniste d'un double récepteur et leurs utilisations
ATE528302T1 (de) 3,5-disubstituierte pyrid-2-one, die als hemmer der tec-familie von nicht-rezeptor tyrosin- kinasen nützlich sind
WO2004108766A3 (fr) Anticorps anti-hgf-r et leur utilisation
WO2008013948A3 (fr) Sites de phosphorylation de tyrosines
WO2008054597A3 (fr) Sites de phosphorylation de tyrosine
NO20061412L (no) Terapi av okulaere foretyrrelser
MX2009003039A (es) Utilizacion de un anticuerpo anti-cd151 para el tratamiento del cancer.
WO2008013934A3 (fr) Sites de phosphorylation de tyrosines
TR200102944T2 (tr) İntegrin reseptör ligandları
ATE499362T1 (de) 3,5-disubstituierte pyrid-2-one, die als hemmer der tec-familie von nicht-rezeptor tyrosin- kinasen nützlich sind
TNSN05315A1 (en) Method of inhibiting receptor tyrosine kinases with an extracellular antagonist and an intracellular antagonist